Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-Current Assets: 2022-2024

Historic Non-Current Assets for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $18.2 million.

  • Taysha Gene Therapies' Non-Current Assets fell 11.03% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year decrease of 11.03%. This contributed to the annual value of $18.2 million for FY2024, which is 20.25% down from last year.
  • Taysha Gene Therapies' Non-Current Assets amounted to $18.2 million in FY2024, which was down 20.25% from $22.9 million recorded in FY2023.
  • Over the past 5 years, Taysha Gene Therapies' Non-Current Assets peaked at $29.9 million during FY2022, and registered a low of $18.2 million during FY2024.
  • In the last 3 years, Taysha Gene Therapies' Non-Current Assets had a median value of $22.9 million in 2023 and averaged $23.7 million.
  • Data for Taysha Gene Therapies' Non-Current Assets shows a maximum YoY decreased of 23.43% (in 2023) over the last 5 years.
  • Over the past 3 years, Taysha Gene Therapies' Non-Current Assets (Yearly) stood at $29.9 million in 2022, then declined by 23.43% to $22.9 million in 2023, then fell by 20.25% to $18.2 million in 2024.